"Amsacrine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
| Descriptor ID |
D000677
|
| MeSH Number(s) |
D03.633.300.046.250.225
|
| Concept/Terms |
Amsacrine- Amsacrine
- Cain's Acridine
- Cain Acridine
- Cains Acridine
- meta-AMSA
- meta AMSA
- AMSA
- m-AMSA
Amsidine- Amsidine
- Amsacrina
- AMSA P-D
- AMSA P D
- AMSA PD
|
Below are MeSH descriptors whose meaning is more general than "Amsacrine".
Below are MeSH descriptors whose meaning is more specific than "Amsacrine".
This graph shows the total number of publications written about "Amsacrine" by people in this website by year, and whether "Amsacrine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 3 | 3 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amsacrine" by people in Profiles.
-
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015 Jan 15; 121(2):234-42.
-
Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. Br J Cancer. 2001 Sep 01; 85(5):747-51.
-
Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha. Cancer Res. 1998 Dec 01; 58(23):5298-300.
-
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Biochemistry. 1997 Mar 11; 36(10):2919-24.
-
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Leuk Lymphoma. 1996 Jun; 22(1-2):71-6.
-
Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. Br J Cancer. 1996 Jun; 73(11):1373-80.
-
Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma. 1996 Feb; 20(5-6):435-9.
-
Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. Oncol Res. 1996; 8(3):101-10.
-
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995 Sep 15; 86(6):2091-7.
-
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 1994 Aug; 8(8):1269-74.